Revenue + Forward P/E
Gilead Sciences, Inc. (GILD) quarterly revenue and forward P/EForward P/E: 15.1x
RevenueRevenue (est)Forward P/E
Fair value & valuation models
Fair value models are a Plus feature
Upgrade to Plus for the interactive DCF model, valuation bands, and implied-price scenarios.
71% OFF$23.99 $6.99/mo
Ends in23:59:59
Cancel anytime. Secure checkout via Stripe.
Valuation
Market cap
$170.42B
Enterprise value
$175.09B
P/E ratio (TTM)
17.43x
P/S ratio (TTM)
5.40x
P/B ratio
6.83x
EV/Sales
5.89x
EV/EBITDA
12.49x
Dividend yield
2.49%
Income statement (TTM)
Revenue (TTM)
$29.44B
Gross profit (TTM)
$23.21B
Operating income (TTM)
$11.70B
EBITDA (TTM)
$13.58B
Net income (TTM)
$8.51B
Free cash flow (TTM)
$9.46B
Margins & returns
Gross margin
79.35%
Operating margin
38.26%
Profit margin
30.99%
Return on equity
42.16%
Return on assets
16.38%
Per-share metrics
EPS (TTM)
$7.42
Dividend yield
2.49%
Beta
0.34
Capital structure
Cash & equivalents
$7.56B
Total debt
$24.59B
Net debt
$17.03B
Shares outstanding
1.24B
Financial health
Current ratio
1.68
Debt / equity
1.08
Debt / assets
0.42
Interest coverage
11.43
| Company | Market cap | P/E | P/S | EV/EBITDA | Div yield |
|---|---|---|---|---|---|
| $1.15T | 42.41x | 15.59x | 34.80x | 0.54% | |
| $630.33B | 30.45x | 6.47x | 20.76x | 1.99% | |
| $443.38B | 127.13x | 7.29x | 30.82x | 2.63% | |
| $365.07B | 27.06x | 0.85x | 16.46x | 2.13% | |
| $354.73B | 23.91x | 4.80x | 15.14x | 2.67% | |
| $333.02B | 36.82x | 4.94x | 19.57x | 2.56% | |
| $170.42B | 17.43x | 5.40x | 12.49x | 2.49% |